EP
Eversept Partners Portfolio holdings
AUM
$992M
This Quarter Return
+14.55%
1 Year Return
+2.54%
3 Year Return
+103.47%
5 Year Return
+181.01%
10 Year Return
–
AUM
$1.3B
AUM Growth
+$1.3B
(-0.24%)
Cap. Flow
-$181M
Cap. Flow
% of AUM
-13.88%
Top 10 Holdings %
Top 10 Hldgs %
62.01%
Holding
84
New
10
Increased
22
Reduced
31
Closed
17
Top Buys
| 1 |
GSK
GSK
|
$24.1M |
| 2 |
ZimVie
ZIMV
|
$20.7M |
| 3 |
Bausch Health
BHC
|
$12.5M |
| 4 |
Bio-Techne
TECH
|
$9.63M |
| 5 |
Syndax Pharmaceuticals
SNDX
|
$9.46M |
Top Sells
| 1 |
Inspire Medical Systems
INSP
|
$54.2M |
| 2 |
Natera
NTRA
|
$38.5M |
| 3 |
United Therapeutics
UTHR
|
$37.4M |
| 4 |
Teva Pharmaceuticals
TEVA
|
$26.8M |
| 5 |
Novo Nordisk
NVO
|
$21M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
IQVIA
IQV
$32.4B
| $3.11M | 0.21% | 13,138 +960 | +8% | +$227K |
|
52
Maravai LifeSciences
MRVI
$350M
| $2.8M | 0.19% | +336,966 | New | +$2.8M |
|
53
Xoma
XOMA
$392M
| $2.5M | 0.17% | 94,289 +2,382 | +3% | +$63.1K |
|
54
InflaRx
IFRX
$108M
| $2.48M | 0.17% | 1,621,787 +54,857 | +4% | +$83.9K |
|
55
Tourmaline Bio
TRML
$601M
| $2.17M | 0.15% | 84,380 -120,401 | -59% | -$3.1M |
|
|
AMRN
56
Amarin Corp
AMRN
$311M
| $2.07M | 0.14% | 3,309,309 -999,218 | -23% | -$626K |
|
|
NVRO
57
DELISTED
NEVRO CORP.
NVRO
| $1.75M | 0.12% | 313,780 -185,615 | -37% | -$1.04M |
|
58
Alector
ALEC
$238M
| $1.55M | 0.11% | 332,756 -208,983 | -39% | -$974K |
|
|
AUTL
59
Autolus Therapeutics
AUTL
$399M
| $1.48M | 0.1% | 406,558 -204,344 | -33% | -$742K |
|
60
Liquidia Corp
LQDA
$2.38B
| $1.38M | 0.09% | 137,949 -235,605 | -63% | -$2.36M |
|
61
Absci
ABSI
$357M
| $1.04M | 0.07% | 272,869 -52,640 | -16% | -$201K |
|
|
JBIO
62
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $1.01M | 0.07% | +485,141 | New | +$1.01M |
|
63
Stoke Therapeutics
STOK
$1.08B
| $639K | 0.04% | 52,006 -9,271 | -15% | -$114K |
|
|
AFMD
64
DELISTED
Affimed
AFMD
| $559K | 0.04% | 166,460 | – | – |
|
65
AC Immune
ACIU
$205M
| $375K | 0.03% | 99,313 | – | – |
|
66
argenx
ARGX
$43.6B
| – | – | -34,593 | Closed | -$14.9M |
|
67
Cytokinetics
CYTK
$4.23B
| – | – | -126,877 | Closed | -$6.87M |
|
68
Guardant Health
GH
$8.41B
| – | – | -99,377 | Closed | -$2.87M |
|
69
Immunovant
IMVT
$2.56B
| – | – | -92,909 | Closed | -$2.45M |
|
70
Eli Lilly
LLY
$657B
| – | – | -21,233 | Closed | -$19.2M |
|
71
Seres Therapeutics
MCRB
$166M
| – | – | -418,208 | Closed | -$303K |
|
72
MoonLake Immunotherapeutics
MLTX
$3.54B
| – | – | -71,596 | Closed | -$3.15M |
|
73
Myriad Genetics
MYGN
$593M
| – | – | -181,961 | Closed | -$4.45M |
|
|
74
Novo Nordisk
NVO
$251B
| – | – | -146,956 | Closed | -$21M |
|
75
Oscar Health
OSCR
$4.31B
| – | – | -310,893 | Closed | -$4.92M |
|